US Bancorp DE Purchases 1,078 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

US Bancorp DE lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.6% during the 4th quarter, Holdings Channel reports. The firm owned 6,066 shares of the biopharmaceutical company’s stock after buying an additional 1,078 shares during the quarter. US Bancorp DE’s holdings in Regeneron Pharmaceuticals were worth $4,321,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Fisher Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 16.5% during the 4th quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company’s stock worth $4,197,000 after acquiring an additional 833 shares during the last quarter. SVB Wealth LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $707,000. Illumine Investment Management LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $2,130,000. Anchor Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $7,727,000. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in Regeneron Pharmaceuticals by 27.7% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,401 shares of the biopharmaceutical company’s stock worth $998,000 after acquiring an additional 304 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on REGN shares. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Bank of America reaffirmed an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, Oppenheimer reduced their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $687.15 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $75.12 billion, a P/E ratio of 17.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company’s 50 day moving average price is $696.58 and its two-hundred day moving average price is $857.92. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $11.86 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.